Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines
P Meij, I Jedema, ML Zandvliet… - Journal of …, 2012 - journals.lww.com
To treat patients with refractory cytomegalovirus (CMV) reactivation after allogeneic stem cell
transplantation, a phase I/II clinical study on adoptive transfer of in vitro-generated donor-
derived or patient-derived CMV pp65-specific CD8+ T-cell lines was performed. Peripheral
blood mononuclear cells from CMV seropositive donors or patients were stimulated with
HLA-A* 0201-restricted and/or HLA-B* 0702-restricted CMV pp65 peptides (NLV/TPR) and 1
day after stimulation interferon-γ)-producing cells were enriched using the CliniMACS …
transplantation, a phase I/II clinical study on adoptive transfer of in vitro-generated donor-
derived or patient-derived CMV pp65-specific CD8+ T-cell lines was performed. Peripheral
blood mononuclear cells from CMV seropositive donors or patients were stimulated with
HLA-A* 0201-restricted and/or HLA-B* 0702-restricted CMV pp65 peptides (NLV/TPR) and 1
day after stimulation interferon-γ)-producing cells were enriched using the CliniMACS …